![PDF) Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis results from REVEAL, a prospective, randomised head-to-head study PDF) Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis results from REVEAL, a prospective, randomised head-to-head study](https://www.researchgate.net/publication/344906693/figure/tbl3/AS:983533531181058@1611504075894/Key-MRI-and-clinical-outcomes_Q320.jpg)
PDF) Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis results from REVEAL, a prospective, randomised head-to-head study
![PDF) Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis results from REVEAL, a prospective, randomised head-to-head study PDF) Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis results from REVEAL, a prospective, randomised head-to-head study](https://www.researchgate.net/publication/344906693/figure/tbl1/AS:983533531185155@1611504075818/Baseline-demographics-and-characteristics_Q320.jpg)
PDF) Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis results from REVEAL, a prospective, randomised head-to-head study
![PDF) Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis results from REVEAL, a prospective, randomised head-to-head study PDF) Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis results from REVEAL, a prospective, randomised head-to-head study](https://i1.rgstatic.net/publication/344906693_Natalizumab_versus_fingolimod_for_patients_with_active_relapsing-remitting_multiple_sclerosis_results_from_REVEAL_a_prospective_randomised_head-to-head_study/links/600d875c92851c13fe33dd9e/largepreview.png)